Arbutus Biopharma Corp Intellectual Property Contracts & Agreements
7 Contracts & Agreements
- License Agreements (7 contracts)
- Technology Transfer and Exclusive License Agreement, dated December 13, 2021, by and between the Company and Qilu Pharmaceutical Co., Ltd (Filed With SEC on March 3, 2022)
- Third Amendment to Cross License Agreement, dated December 9, 2021, by and between Genevant Sciences GmbH and Arbutus Biopharma Corporation (Filed With SEC on December 10, 2021)
- Second Amendment to Cross License Agreement, dated June 27, 2018, by and among the Company, Genevant Sciences Ltd. And Genevant Sciences GmbH (Filed With SEC on August 7, 2020)
- First Amendment to Cross License Agreement, dated June 27, 2018, by and among the Company, Genevant Sciences Ltd. And Genevant Sciences GmbH (Filed With SEC on August 7, 2020)
- Cross License Agreement, dated April 11, 2018, by and between the Company and Genevant Sciences Ltd (Filed With SEC on August 7, 2020)
- LICENSE AGREEMENT by and between ALEXION PHARMA HOLDING on the one hand, and ARBUTUS BIOPHARMA CORPORATION and PROTIVA BIOTHERAPEUTICS INC., on the other hand Dated as of March... (Filed With SEC on March 22, 2017)
- License Agreement between OnCore Biopharma, Inc. and Cytos Biotechnology Ltd. dated December 30, 2014 (Filed With SEC on November 5, 2015)
